Strategy (MSTR) shares have fallen 30% since its executive chairman and former CEO, Michael Saylor, was featured on the cover of Forbes, according to stock price data from Yahoo Finance.

It signals a potential evolution in market capital strategies. Michael Saylor’s firm, Strategy, will offer $21 billion in preferred stock as a means of building up its Bitcoin stockpile, a March 10 ...

Michael Saylor, Strategy’s co-founder and chairman, also presented a broader crypto strategy at the White House Digital Assets Summit. He projected that the US could unlock up to $100 trillion ...

Despite the severe correction in Bitcoin price and market volatility, Michael Saylor seems confident about his BTC accumulation strategy. The firm has been consistently purchasing Bitcoin almost ...

Strategy's raise is part of a plan to finance its Bitcoin buying. Michael Saylor was most recently with US President Donald Trump during Friday’s crypto summit. Strategy just announced plans to raise ...

“I was born, and they took a picture,” says Liza Minnelli, expressing the reality of growing up in the flashbulb-popping, gossip-saturated spotlight as Hollywood royalty—as the daughter of ...

Strategy executive chairman Michael Saylor is unveiling an ambitious plan to bolster the company’s already boisterous Bitcoin (BTC) holdings. In a new post to the social media platform X, Saylor says ...

Six people are facing multiple charges after an anti-human trafficking operation in Morgan County, according to the sheriff's office. The Morgan County Sheriff's Office Criminal Investigation ...

Michael Saylor, the executive chairman of Strategy (formerly known as MicroStrategy), said at Friday's White House crypto summit that pro-crypto policies and leadership could boost the U.S ...

Strategy co-founder Michael Saylor shared a comprehensive cryptocurrency strategy at the White House Digital Assets Summit, arguing that the U.S. can unlock up to $100 trillion in economic value ...

In a report released on March 6, Anupam Rama from J.P. Morgan maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price target of $45.00. The company’s shares closed ...